# Drug Repurposing Hypothesis Cards

**Generated**: 2026-02-08 06:06:38
**Total Candidates**: 8

## Summary

- ✅ **GO**: 2 drugs
- ⚠️ **MAYBE**: 1 drugs
- ❌ **NO-GO**: 5 drugs

---

# Resveratrol

**Drug ID**: D81B744A593
**Decision**: GO

## Scores

**Total Score**: 98.0/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 30.0 | 30 |
| Mechanism Plausibility | 20.0 | 20 |
| Translatability | 20.0 | 20 |
| Safety Fit | 20.0 | 20 |
| Practicality | 8.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 80
- **Benefit Papers**: 17
- **Harm Papers**: 0
- **Neutral Papers**: 0
- **Unknown/Unclear**: 3

## Hypothesized Mechanism

Resveratrol may reduce atherosclerosis through anti-inflammatory effects, lipid modulation, macrophage modulation. Based on 17 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.

## Key Supporting Evidence

1. PMID:40043912 - https://pubmed.ncbi.nlm.nih.gov/40043912/
2. PMID:24895526 - https://pubmed.ncbi.nlm.nih.gov/24895526/
3. PMID:27156686 - https://pubmed.ncbi.nlm.nih.gov/27156686/
4. PMID:30885430 - https://pubmed.ncbi.nlm.nih.gov/30885430/
5. PMID:26306466 - https://pubmed.ncbi.nlm.nih.gov/26306466/

## Recommended Next Steps

- ✅ Proceed to detailed validation planning
- Review full evidence dossier and identify key mechanistic papers
- Design preclinical validation experiments (if mechanism unclear)
- Evaluate clinical trial feasibility and endpoints
- Assess drug availability and regulatory pathway

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/D81B744A593__resveratrol.json`

---

# Dexamethasone

**Drug ID**: DD76A1941B2
**Decision**: GO

## Scores

**Total Score**: 94.0/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 30.0 | 30 |
| Mechanism Plausibility | 20.0 | 20 |
| Translatability | 20.0 | 20 |
| Safety Fit | 16.0 | 20 |
| Practicality | 8.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 80
- **Benefit Papers**: 18
- **Harm Papers**: 0
- **Neutral Papers**: 0
- **Unknown/Unclear**: 2

## Hypothesized Mechanism

Dexamethasone may reduce atherosclerosis through anti-inflammatory effects, lipid modulation, macrophage modulation, plaque stabilization/regression. Based on 18 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.

## Key Supporting Evidence

1. PMID:8499410 - https://pubmed.ncbi.nlm.nih.gov/8499410/
2. PMID:40239267 - https://pubmed.ncbi.nlm.nih.gov/40239267/
3. PMID:16815711 - https://pubmed.ncbi.nlm.nih.gov/16815711/
4. PMID:30478968 - https://pubmed.ncbi.nlm.nih.gov/30478968/
5. PMID:34784501 - https://pubmed.ncbi.nlm.nih.gov/34784501/

## Recommended Next Steps

- ✅ Proceed to detailed validation planning
- Review full evidence dossier and identify key mechanistic papers
- Design preclinical validation experiments (if mechanism unclear)
- Evaluate clinical trial feasibility and endpoints
- Assess drug availability and regulatory pathway

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/DD76A1941B2__dexamethasone.json`

---

# Nicotinamide Riboside

**Drug ID**: D8291C5A5C4
**Decision**: MAYBE
**Reasons**: score<60.0

## Scores

**Total Score**: 59.1/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 13.4 | 30 |
| Mechanism Plausibility | 13.7 | 20 |
| Translatability | 12.0 | 20 |
| Safety Fit | 16.0 | 20 |
| Practicality | 4.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 11
- **Benefit Papers**: 5
- **Harm Papers**: 2
- **Neutral Papers**: 0
- **Unknown/Unclear**: 4

## Hypothesized Mechanism

Nicotinamide Riboside shows evidence of benefit in 5 publications. Specific mechanism requires further investigation of literature.

## Key Supporting Evidence

1. PMID:38871717 - https://pubmed.ncbi.nlm.nih.gov/38871717/
2. PMID:39034866 - https://pubmed.ncbi.nlm.nih.gov/39034866/
3. PMID:35196876 - https://pubmed.ncbi.nlm.nih.gov/35196876/
4. PMID:40257024 - https://pubmed.ncbi.nlm.nih.gov/40257024/
5. PMID:32758058 - https://pubmed.ncbi.nlm.nih.gov/32758058/

## Recommended Next Steps

- ⚠️ Borderline candidate - requires additional evidence review
- Manual review of top 20 papers to confirm benefit/harm classification
- Search for additional evidence (expanded PubMed queries)
- Gather more evidence - current coverage may be insufficient
- Re-score after evidence review to determine GO/NO-GO

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/D8291C5A5C4__nicotinamide_riboside.json`

---

# Apolipoprotein A-I Human Apoa-I

**Drug ID**: D4BE4598792
**Decision**: NO-GO
**Reasons**: safety_concern

## Scores

**Total Score**: 84.0/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 26.7 | 30 |
| Mechanism Plausibility | 17.3 | 20 |
| Translatability | 20.0 | 20 |
| Safety Fit | 12.0 | 20 |
| Practicality | 8.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 80
- **Benefit Papers**: 12
- **Harm Papers**: 6
- **Neutral Papers**: 0
- **Unknown/Unclear**: 2

## Hypothesized Mechanism

Apolipoprotein A-I Human Apoa-I may reduce atherosclerosis through anti-inflammatory effects, plaque stabilization/regression. Based on 12 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.

## Key Supporting Evidence

1. PMID:31567014 - https://pubmed.ncbi.nlm.nih.gov/31567014/
2. PMID:18287885 - https://pubmed.ncbi.nlm.nih.gov/18287885/
3. PMID:28069582 - https://pubmed.ncbi.nlm.nih.gov/28069582/
4. PMID:28939717 - https://pubmed.ncbi.nlm.nih.gov/28939717/
5. PMID:40263360 - https://pubmed.ncbi.nlm.nih.gov/40263360/

## Recommended Next Steps

- ❌ Do not advance to validation at this time
- Archive dossier for future reference

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/D4BE4598792__apolipoprotein_a-i_human_apoa-i.json`

---

# Apolipoprotein A-I Human Apoa-I

**Drug ID**: D4BE4598792
**Decision**: NO-GO
**Reasons**: safety_concern

## Scores

**Total Score**: 74.4/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 23.7 | 30 |
| Mechanism Plausibility | 14.7 | 20 |
| Translatability | 18.0 | 20 |
| Safety Fit | 12.0 | 20 |
| Practicality | 6.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 20
- **Benefit Papers**: 10
- **Harm Papers**: 7
- **Neutral Papers**: 0
- **Unknown/Unclear**: 3

## Hypothesized Mechanism

Apolipoprotein A-I Human Apoa-I may reduce atherosclerosis through anti-inflammatory effects, antioxidant activity, lipid modulation. Based on 10 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.

## Key Supporting Evidence

1. PMID:35120132 - https://pubmed.ncbi.nlm.nih.gov/35120132/
2. PMID:33861588 - https://pubmed.ncbi.nlm.nih.gov/33861588/
3. PMID:28069582 - https://pubmed.ncbi.nlm.nih.gov/28069582/
4. PMID:24407029 - https://pubmed.ncbi.nlm.nih.gov/24407029/
5. PMID:29437574 - https://pubmed.ncbi.nlm.nih.gov/29437574/

## Recommended Next Steps

- ❌ Do not advance to validation at this time
- Archive dossier for future reference

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/D4BE4598792__apolipoprotein_a-i_human_apoa-i_embed.json`

---

# Medi6570

**Drug ID**: D413D3EC269
**Decision**: NO-GO
**Reasons**: pmids<3

## Scores

**Total Score**: 49.1/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 8.1 | 30 |
| Mechanism Plausibility | 14.0 | 20 |
| Translatability | 6.0 | 20 |
| Safety Fit | 20.0 | 20 |
| Practicality | 1.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 2
- **Benefit Papers**: 2
- **Harm Papers**: 0
- **Neutral Papers**: 0
- **Unknown/Unclear**: 0

## Hypothesized Mechanism

Medi6570 may reduce atherosclerosis through anti-inflammatory effects. Based on 2 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.

## Key Supporting Evidence

1. PMID:36688371 - https://pubmed.ncbi.nlm.nih.gov/36688371/
2. PMID:40999229 - https://pubmed.ncbi.nlm.nih.gov/40999229/

## Recommended Next Steps

- ❌ Do not advance to validation at this time
- Limited literature - may indicate insufficient research interest
- Archive dossier for future reference

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/D413D3EC269__medi6570.json`

---

# Vm202

**Drug ID**: DF09C894FE9
**Decision**: NO-GO
**Reasons**: benefit<2; pmids<3

## Scores

**Total Score**: 43.1/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 4.1 | 30 |
| Mechanism Plausibility | 14.0 | 20 |
| Translatability | 4.0 | 20 |
| Safety Fit | 20.0 | 20 |
| Practicality | 1.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 2
- **Benefit Papers**: 1
- **Harm Papers**: 0
- **Neutral Papers**: 0
- **Unknown/Unclear**: 1

## Hypothesized Mechanism

Vm202 shows evidence of benefit in 1 publications. Specific mechanism requires further investigation of literature.

## Key Supporting Evidence

1. PMID:21430785 - https://pubmed.ncbi.nlm.nih.gov/21430785/

## Recommended Next Steps

- ❌ Do not advance to validation at this time
- Insufficient benefit evidence - consider removing from pipeline
- Limited literature - may indicate insufficient research interest
- Archive dossier for future reference

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/DF09C894FE9__vm202.json`

---

# Creatine Monohydrate

**Drug ID**: D9F9BB8C160
**Decision**: NO-GO
**Reasons**: benefit<2; pmids<3

## Scores

**Total Score**: 31.1/100

| Dimension | Score | Max |
|-----------|-------|-----|
| Evidence Strength | 0.1 | 30 |
| Mechanism Plausibility | 6.0 | 20 |
| Translatability | 4.0 | 20 |
| Safety Fit | 20.0 | 20 |
| Practicality | 1.0 | 10 |

## Evidence Summary

- **Total PMIDs**: 2
- **Benefit Papers**: 0
- **Harm Papers**: 0
- **Neutral Papers**: 0
- **Unknown/Unclear**: 2

## Hypothesized Mechanism

Limited evidence available for creatine monohydrate in atherosclerosis. Mechanism unclear.

## Recommended Next Steps

- ❌ Do not advance to validation at this time
- Insufficient benefit evidence - consider removing from pipeline
- Limited literature - may indicate insufficient research interest
- Archive dossier for future reference

## Detailed Dossier

Full evidence dossier: `output/step6_simple/dossiers/D9F9BB8C160__creatine_monohydrate.json`

---
